Robin Kramer - Feb 10, 2023 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
Chief Accounting Officer
Signature
/s/ Wendell Taylor, attorney-in-fact for Robin Kramer
Stock symbol
BIIB
Transactions as of
Feb 10, 2023
Transactions value $
-$168,917
Form type
4
Date filed
2/14/2023, 08:37 PM
Previous filing
Feb 10, 2023
Next filing
Feb 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIIB Common Stock Options Exercise $0 +833 +26.88% $0.00 3.93K Feb 10, 2023 Direct
transaction BIIB Common Stock Tax liability -$75K -262 -6.66% $286.30 3.67K Feb 10, 2023 Direct
transaction BIIB Common Stock Options Exercise $0 +228 +6.21% $0.00 3.9K Feb 10, 2023 Direct
transaction BIIB Common Stock Tax liability -$19.2K -67 -1.72% $286.30 3.83K Feb 10, 2023 Direct
transaction BIIB Common Stock Tax liability -$74.7K -261 -6.81% $286.30 3.57K Feb 10, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Restricted Stock Unit Options Exercise $0 -833 -33.32% $0.00 1.67K Feb 10, 2023 Common Stock 833 $0.00 Direct F2
transaction BIIB Restricted Stock Unit Options Exercise $0 -228 -45.06% $0.00 278 Feb 10, 2023 Common Stock 228 $0.00 Direct F3
transaction BIIB Restricted Stock Unit Other $0 -278 -100% $0.00* 0 Feb 10, 2023 Common Stock 278 $0.00 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023.
F2 The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.
F3 This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F4 This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.